Poor clinical outcomes associated with community-onset urinary tract infections due to extended-spectrum cephalosporin-resistant Enterobacteriaceae
- PMID: 30375298
- PMCID: PMC6289636
- DOI: 10.1017/ice.2018.254
Poor clinical outcomes associated with community-onset urinary tract infections due to extended-spectrum cephalosporin-resistant Enterobacteriaceae
Abstract
Objective: Resistance to extended-spectrum cephalosporins (ESC) among Enterobacteriaceae (EB) is increasingly prevalent. We sought to determine the clinical outcomes associated with community-onset ESC-resistant (ESC-R) EB urinary tract infections (UTIs) in a US health system.
Design: Retrospective cohort study.PatientsAll patients presenting to the emergency departments (EDs) or outpatient practices with EB UTIs between 2010 and 2013 were included. Exposed patients had ESC-R EB UTIs. Unexposed patients had ESC-susceptible EB UTIs and were matched to exposed subjects 1:1 on study year. Multivariable logistic regression analyses were performed to evaluate the association between ESC-R EB UTI and the outcomes of clinical failure and inappropriate initial antibiotic therapy (IIAT).
Results: A total of 302 patients with community-onset EB UTI were included, with 151 exposed and unexposed. On multivariable analyses, UTI due to an ESC-R EB was significantly associated with clinical failure (odds ratio [OR], 7.07; 95% confidence interval [CI], 3.16-15.82; P<.01). Other independent risk factors for clinical failure included infection with Citrobacter spp and need for hemodialysis. UTI due to an ESC-R EB was also significantly associated with IIAT (OR, 4.40; 95% CI, 2.64-7.33; P<.01).
Conclusions: Community-onset UTI due to an ESC-R EB organism is significantly associated with clinical failure, which may be due in part to IIAT. Further studies are needed to determine which patients in the community are at high risk for drug-resistant infection to help inform prompt diagnosis and appropriate antibiotic prescribing for ESC-R EB.
Conflict of interest statement
Similar articles
-
The role of extended-spectrum cephalosporin-resistance in recurrent community-onset Enterobacteriaceae urinary tract infections: a retrospective cohort study.BMC Infect Dis. 2019 Feb 14;19(1):163. doi: 10.1186/s12879-019-3804-y. BMC Infect Dis. 2019. PMID: 30764770 Free PMC article.
-
Clinical and Molecular Characterization of Community-Onset Urinary Tract Infections Due to Extended-Spectrum Cephalosporin-Resistant Enterobacteriaceae.Infect Control Hosp Epidemiol. 2016 Dec;37(12):1433-1439. doi: 10.1017/ice.2016.225. Epub 2016 Sep 28. Infect Control Hosp Epidemiol. 2016. PMID: 27678022 Free PMC article.
-
Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.Ann Emerg Med. 2018 Oct;72(4):449-456. doi: 10.1016/j.annemergmed.2018.05.006. Epub 2018 Jul 3. Ann Emerg Med. 2018. PMID: 29980462
-
[Epidemiology and etiology of urinary tract infections in the community. Antimicrobial susceptibility of the main pathogens and clinical significance of resistance].Enferm Infecc Microbiol Clin. 2005 Dec;23 Suppl 4:3-8. doi: 10.1157/13091442. Enferm Infecc Microbiol Clin. 2005. PMID: 16854352 Review. Spanish.
-
Clinical evaluation of guidelines and therapeutic approaches in multi drug-resistant urinary tract infections.J Chemother. 2017 Dec;29(sup1):19-28. doi: 10.1080/1120009X.2017.1380397. J Chemother. 2017. PMID: 29271735 Review.
Cited by
-
Risk Factors for Recurrence of Community-Onset Urinary Tract Infections Caused by Extended-Spectrum Cephalosporin-Resistant Enterobacterales.Open Forum Infect Dis. 2023 Nov 8;10(12):ofad561. doi: 10.1093/ofid/ofad561. eCollection 2023 Dec. Open Forum Infect Dis. 2023. PMID: 38130594 Free PMC article.
-
The Clinical Implications of Inappropriate Therapy in Community-Onset Urinary Tract Infections and the Development of a Bayesian Hierarchical Weighted-Incidence Syndromic Combination Antibiogram.Antibiotics (Basel). 2025 Feb 12;14(2):187. doi: 10.3390/antibiotics14020187. Antibiotics (Basel). 2025. PMID: 40001430 Free PMC article.
-
Clinical Risk Scores to Predict Nonsusceptibility to Trimethoprim-Sulfamethoxazole, Fluoroquinolone, Nitrofurantoin, and Third-Generation Cephalosporin Among Adult Outpatient Episodes of Complicated Urinary Tract Infection.Open Forum Infect Dis. 2023 Jun 14;10(8):ofad319. doi: 10.1093/ofid/ofad319. eCollection 2023 Aug. Open Forum Infect Dis. 2023. PMID: 37534299 Free PMC article.
-
The Five Ds of Outpatient Antibiotic Stewardship for Urinary Tract Infections.Clin Microbiol Rev. 2021 Dec 15;34(4):e0000320. doi: 10.1128/CMR.00003-20. Epub 2021 Aug 25. Clin Microbiol Rev. 2021. PMID: 34431702 Free PMC article. Review.
-
Development of Predictive Models to Inform a Novel Risk Categorization Framework for Antibiotic Resistance in Escherichia coli-Caused Uncomplicated Urinary Tract Infection.Clin Infect Dis. 2024 Aug 16;79(2):295-304. doi: 10.1093/cid/ciae171. Clin Infect Dis. 2024. PMID: 38573310 Free PMC article.
References
-
- Pitout JD, Hanson ND, Church DL, Laupland KB. Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes. Clin Infect Dis 2004;38:1736–1741. - PubMed
-
- Canton R, Novais A, Valverde A, et al. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 2008;14 Suppl 1:144–153. - PubMed
-
- Rodriguez-Bano J, Navarro MD, Romero L, et al. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006;43:1407–1414. - PubMed
-
- Ben-Ami R, Schwaber MJ, Navon-Venezia S, et al. Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis 2006;42:925–934. - PubMed
-
- Simonsen L, Conn LA, Pinner RW, Teutsch S. Trends in infectious disease hospitalizations in the United States, 1980–1994. Arch Intern Med 1998;158:1923–1928. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous